Receptor News and Research

RSS

Researchers reveal new molecular mechanisms that resist visceral leishmaniasis

Researchers from CNRS, Université Toulouse III - Paul Sabatier and IRD have elucidated new molecular mechanisms involved in resistance to visceral leishmaniasis, a serious parasitic infection.

16 May 2013

Study suggests need for better anti-rejection therapies

Transplant researchers at the University of Pittsburgh School of Medicine challenge a long-held assumption about how biologic pathways trigger immune system rejection of donor organs in a report published online today in the Journal of Clinical Investigation.

16 May 2013

Avian-origin influenza A virus associated with severe lower respiratory tract diseases

A novel avian-origin reassortant influenza A (H7N9) virus emerged in China in February 2013, and is associated with severe lower respiratory tract diseases. To date, more than 100 human cases of infection, including at least 20 deaths, have been reported in China.

15 May 2013

Sanofi, Regeneron enroll patients in two sarilumab Phase 3 trials for treatment of RA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the COMPARE and ASCERTAIN trials of sarilumab, the first fully human monoclonal antibody directed against the IL-6 receptor, which is delivered by subcutaneous injection every other week, have enrolled their first patients.

15 May 2013

New study reveals another duet played by Notch and BMP signals

A small ensemble of musicians can produce an infinite number of melodies, harmonies and rhythms. So too, do a handful of workhorse signaling pathways that interact to construct multiple structures that comprise the vertebrate body.

15 May 2013

FDA OKs TWi Pharmaceuticals' tentative ANDA for Guanfacine Hydrochloride Extended Release Tablets

TWi Pharmaceuticals, Inc. today announced that it has received tentative approval for its Abbreviated New Drug Application for Guanfacine Hydrochloride Extended Release Tablets 1mg, 2mg, 3mg and 4mg from the United States Food and Drug Administration.

14 May 2013

Discovery provides vital clues for new antibiotics against MRSA

Scientists at Imperial College London have identified four new proteins that act as receptors for an essential signalling molecule in bacteria such as MRSA.

14 May 2013

Cancers physically alter cells in lymphatic system to promote the spread of disease

Researchers at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center report that cancers physically alter cells in the lymphatic system - a network of vessels that transports and stores immune cells throughout the body - to promote the spread of disease, a process called metastasis.

14 May 2013

Chinese scientists suggest strong measures to prevent a possible pandemic

On 31 March 2013, the Chinese National Health and Family Planning Commission announced human cases of novel H7N9 influenza virus infections.

14 May 2013

Researchers successfully test new anti-cocaine vaccine in primates

Researchers at Weill Cornell Medical College have successfully tested their novel anti-cocaine vaccine in primates, bringing them closer to launching human clinical trials.

13 May 2013

Study results suggest that CNL and aCML patients could be treated with FDA-approved drugs

Patients with two forms of leukemia, who currently have no viable treatment options, may benefit from existing drugs developed for different types of cancer, according to a study conducted by researchers at the Knight Cancer Institute at Oregon Health & Science University.

13 May 2013

Drug resistant brain tumors: an interview with Prof. Mischel, Ludwig Institute for Cancer Research and Prof. Bensinger, University of California

In cancer, mutations in proteins that control cell growth are common, leading to unrestrained cellular proliferation and tumor formation.

9 May 2013

Trevena, Forest sign collaborative agreement to develop TRV027 for treatment of ADHF

Trevena, Inc., a clinical stage pharmaceutical company and the leader in the discovery and development of G-protein coupled receptor biased ligands, and Forest Laboratories Holding Limited, a subsidiary of Forest Laboratories Inc., an international pharmaceutical company, announced today that they have entered into a collaborative licensing option agreement for the development of TRV027, an AT1R biased-ligand that recently completed Phase 2a clinical trials.

9 May 2013

Researchers discover that microRNAs link two defining characteristics of fit muscles

Researchers discovered that small pieces of genetic material called microRNAs link the two defining characteristics of fit muscles: the ability to burn sugar and fat and the ability to switch between slow- and fast-twitch muscle fibers.

9 May 2013

Phase 1b clinical study data of EBI-005 for treatment of dry eye disease presented at ARVO meeting

Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics for ocular diseases, announced today the presentation of data for EBI-005, the first IL-1 (Interleukin-1) signaling inhibitor designed for topical ocular administration, at the Association for Research in Vision and Ophthalmology 2013 Annual Meeting in Seattle, Washington.

9 May 2013

Patients with ASPS appear to benefit from anti-cancer drug, cediranib

Patients with advanced alveolar soft part sarcoma (ASPS), a rare cancer, achieved some control of their disease using an experimental anti-cancer drug called cediranib.

8 May 2013

Scientists reexamine gene strongly linked to Alzheimer's disease

Scientists' picture of how a gene strongly linked to Alzheimer's disease harms the brain may have to be revised, researchers at Washington University School of Medicine in St. Louis have found. People with harmful forms of the APOE gene have up to 12 times the risk of developing Alzheimer's disease compared with those who have other variations of the gene.

8 May 2013

New therapeutic targets for reducing heart disease in people with type 1 diabetes

Type 1 (insulin-dependent) diabetes appears to increase the risk of heart disease, the leading cause of death among people with high blood sugar, partly by stimulating the production of calprotectin, a protein that sparks an inflammatory process that fuels the buildup of artery-clogging plaque.

8 May 2013

Protein tumor necrosis factor-alpha is a powerful weapon to control cancer

The protein tumor necrosis factor-alpha (TNF-alpha) is a powerful weapon in the arsenal to control cancer. Unfortunately, as is the case with many potent cancer therapies, the use of TNF-alpha as an anti-cancer therapy has been severely limited.

8 May 2013

Seven-year quest to understand how breast cancer cells resist treatment

A seven-year quest to understand how breast cancer cells resist treatment with the targeted therapy lapatinib has revealed a previously unknown molecular network that regulates cell death.

8 May 2013

Receptor News and Research

Researchers reveal new molecular mechanisms that resist visceral leishmaniasis

Study suggests need for better anti-rejection therapies

Avian-origin influenza A virus associated with severe lower respiratory tract diseases

Sanofi, Regeneron enroll patients in two sarilumab Phase 3 trials for treatment of RA

New study reveals another duet played by Notch and BMP signals

FDA OKs TWi Pharmaceuticals' tentative ANDA for Guanfacine Hydrochloride Extended Release Tablets

Discovery provides vital clues for new antibiotics against MRSA

Cancers physically alter cells in lymphatic system to promote the spread of disease

Chinese scientists suggest strong measures to prevent a possible pandemic

Researchers successfully test new anti-cocaine vaccine in primates

Study results suggest that CNL and aCML patients could be treated with FDA-approved drugs

Drug resistant brain tumors: an interview with Prof. Mischel, Ludwig Institute for Cancer Research and Prof. Bensinger, University of California

Trevena, Forest sign collaborative agreement to develop TRV027 for treatment of ADHF

Researchers discover that microRNAs link two defining characteristics of fit muscles

Phase 1b clinical study data of EBI-005 for treatment of dry eye disease presented at ARVO meeting

Patients with ASPS appear to benefit from anti-cancer drug, cediranib

Scientists reexamine gene strongly linked to Alzheimer's disease

New therapeutic targets for reducing heart disease in people with type 1 diabetes

Protein tumor necrosis factor-alpha is a powerful weapon to control cancer

Seven-year quest to understand how breast cancer cells resist treatment

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News